JP2022533759A5 - - Google Patents

Info

Publication number
JP2022533759A5
JP2022533759A5 JP2021569344A JP2021569344A JP2022533759A5 JP 2022533759 A5 JP2022533759 A5 JP 2022533759A5 JP 2021569344 A JP2021569344 A JP 2021569344A JP 2021569344 A JP2021569344 A JP 2021569344A JP 2022533759 A5 JP2022533759 A5 JP 2022533759A5
Authority
JP
Japan
Prior art keywords
composition
item
composition according
approximately
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021569344A
Other languages
English (en)
Japanese (ja)
Other versions
JP7579811B2 (ja
JP2022533759A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/034269 external-priority patent/WO2020237170A1/en
Publication of JP2022533759A publication Critical patent/JP2022533759A/ja
Publication of JP2022533759A5 publication Critical patent/JP2022533759A5/ja
Application granted granted Critical
Publication of JP7579811B2 publication Critical patent/JP7579811B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021569344A 2019-05-22 2020-05-22 テルリプレシンの製剤 Active JP7579811B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962851366P 2019-05-22 2019-05-22
US62/851,366 2019-05-22
PCT/US2020/034269 WO2020237170A1 (en) 2019-05-22 2020-05-22 Formulations of terlipressin

Publications (3)

Publication Number Publication Date
JP2022533759A JP2022533759A (ja) 2022-07-25
JP2022533759A5 true JP2022533759A5 (https=) 2023-11-24
JP7579811B2 JP7579811B2 (ja) 2024-11-08

Family

ID=73458147

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021569344A Active JP7579811B2 (ja) 2019-05-22 2020-05-22 テルリプレシンの製剤

Country Status (11)

Country Link
US (3) US12156898B2 (https=)
EP (1) EP3972628A4 (https=)
JP (1) JP7579811B2 (https=)
KR (1) KR20220011697A (https=)
CN (1) CN114096267B (https=)
AU (1) AU2020279395B2 (https=)
BR (1) BR112021023274A2 (https=)
CA (1) CA3141488A1 (https=)
CL (1) CL2021003065A1 (https=)
MX (1) MX2021014310A (https=)
WO (1) WO2020237170A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020013389A (es) 2018-06-15 2021-03-31 Ferring Bv Composiciones de terlipresina y usos de las mismas.
US20240156895A1 (en) * 2022-10-28 2024-05-16 Mallinckrodt Pharmaceuticals Ireland Limited Compositions for improving kidney function in patients with hepatorenal syndrome
CN115856149B (zh) * 2022-12-26 2023-12-05 哈尔滨吉象隆生物技术有限公司 一种特利加压素中杂质的检测方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482931A (en) 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
AT409081B (de) 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
EP1188443A1 (en) 2000-09-15 2002-03-20 Ferring BV Improved protocol for paracentesis
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US20040153032A1 (en) * 2002-04-23 2004-08-05 Garribotto John T. Dispenser for patient infusion device
US6991800B2 (en) 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
US20040022792A1 (en) * 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
CA2512788A1 (en) * 2003-01-09 2004-07-29 Baxter Healthcare S.A. Safety containers for biologically active substances and method for producing said container
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
DK1984012T3 (en) 2006-02-13 2016-03-29 Ferring Bv USE OF peptidic vasopressin receptor agonists
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
CN101677948A (zh) 2007-06-07 2010-03-24 纳斯泰克制药公司 卡贝缩宫素鼻用制剂和治疗孤独症的方法
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
WO2009037586A2 (en) 2007-08-14 2009-03-26 Ferring B.V. Use of peptidic vasopressin receptor agonists
EP2203172A2 (en) 2007-09-28 2010-07-07 Ferring B.V. Use of v2 receptor antagonists in combination with vasopressinergic agonists
WO2009062174A1 (en) 2007-11-08 2009-05-14 University Of Utah Research Foundation Use of angiogenesis antagonists in conditions of abnormal venous proliferation
US8420081B2 (en) 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
US8815232B2 (en) 2008-08-26 2014-08-26 Kyon Biotech Ag Compositions and methods for treating cancer
EP2161030A1 (en) * 2008-09-09 2010-03-10 Rijksuniversiteit te Groningen Oxytocin formulations and uses thereof
EP2344200A2 (en) * 2008-09-19 2011-07-20 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
MX2011004199A (es) 2008-10-20 2011-05-24 Abbott Lab Anticuerpos que unen a il-18 y metodos para purificar los mismos.
US20100203014A1 (en) 2009-02-04 2010-08-12 Aegis Therapeutics Llc Zwitterionic buffered acidic peptide and protein formulations
CN102369296A (zh) 2009-03-09 2012-03-07 生物蛋白有限公司 Mirac蛋白
CN104434894A (zh) 2009-06-08 2015-03-25 Ucl商业有限公司 使用l-鸟氨酸苯乙酸盐治疗门静脉高压和恢复肝功能
WO2010149213A1 (en) * 2009-06-24 2010-12-29 Nokia Siemens Networks Oy Network element for changing the timeslot type according to the received information
US8613892B2 (en) * 2009-06-30 2013-12-24 Abbott Diabetes Care Inc. Analyte meter with a moveable head and methods of using the same
KR20130026504A (ko) 2010-07-14 2013-03-13 큠버랜드 에멀징 테크놀로지스 아이앤씨 트롬복산-a2 수용체 길항제를 이용한 간신증후군 및 간성뇌증의 치료방법
JO3400B1 (ar) 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
CN102440957B (zh) 2011-12-16 2013-09-25 深圳市健元医药科技有限公司 醋酸特利加压素鼻腔喷雾剂及其制备方法
WO2013106072A1 (en) 2012-01-10 2013-07-18 Sorbent Therapeutics, Inc. Compositions comprising crosslinked cation-binding polymers and uses thereof
JO3109B1 (ar) 2012-05-10 2017-09-20 Ferring Bv منبهات لمستقبلات v1a
CA2891281C (en) 2012-11-12 2023-11-28 The Regents Of The University Of Colorado, A Body Corporate Disease severity index for assessment of chronic liver disease and method for diagnosis of three distinct subtypes of primary sclerosing cholangitis
EP2988770A4 (en) 2013-04-26 2016-12-14 La Jolla Pharma Co COMPOSITIONS AND METHOD FOR TREATING KIDNEY FAILURES
US20150056194A1 (en) 2013-08-21 2015-02-26 Georgia Regents Research Institute, Inc. Modified green tea polyphenols and methods thereof for treating liver disease
US20150328317A1 (en) 2014-05-13 2015-11-19 Eagle Pharmaceuticals, Inc. Aqueous buffer-free bivalirudin compositions
US20200046798A1 (en) 2014-10-24 2020-02-13 Mallinckrodt Hospital Products IP Limited Method of treating patients with hepatorenal syndrome type 1
US10335452B2 (en) 2014-10-24 2019-07-02 Mallinckrodt Hospital Products IP Limited Method of treating patients with hepatorenal syndrome type 1
US20200237856A1 (en) 2014-10-24 2020-07-30 Mallinckrodt Hospital Products IP Limited Method of treating patients with hepatorenal syndrome type 1
WO2017150824A1 (ko) 2016-03-03 2017-09-08 가천대학교 산학협력단 마이크로 니들 및 이의 제조방법
CN109462995A (zh) * 2016-05-04 2019-03-12 波涛生命科学有限公司 生物活性剂的方法和组合物
GB201721846D0 (en) 2017-12-22 2018-02-07 Arecor Ltd Novel composition
WO2019180561A1 (en) * 2018-03-20 2019-09-26 Mankind Pharma Ltd. Stable pharmaceutical composition of vasopressin
MX2020013389A (es) * 2018-06-15 2021-03-31 Ferring Bv Composiciones de terlipresina y usos de las mismas.
CN108659104B (zh) * 2018-07-03 2020-06-09 北京市新里程医药科技有限公司 一种特利加压素的制备方法及其药物组合物
CN109010795B (zh) 2018-09-12 2021-10-22 南京康舟医药科技有限公司 醋酸特利加压素注射液以及其制备方法
US20220080023A1 (en) 2018-12-21 2022-03-17 Arecor Limited Novel composition

Similar Documents

Publication Publication Date Title
JP2022533759A5 (https=)
FI3506886T3 (fi) Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä
US10815287B2 (en) Acylated derivative of human insulin or analogue thereof
IL291556B1 (en) Methods and compositions for administration of arylsulfatase A to the central nervous system
JP2018528242A5 (https=)
US8877817B2 (en) Stable ready to use injectable paracetamol formulation
US12220441B2 (en) Formulations of vancomycin
US12564562B2 (en) Injectable epinephrine formulations demonstrating stability over time
BR112020006950A2 (pt) composições farmacêuticas injetáveis estabilizadas de l-epinefrina
JP2003509351A5 (https=)
US20250249066A1 (en) Formulations of Terlipressin
JP2019537589A5 (https=)
EP3528786B1 (en) Liquid formulations of daptomycin
TWI334352B (en) Vinflunine pharmaceutical composition for parenteral administration, preparation process and use thereof
US20170136097A1 (en) Rapid-acting insulin composition comprising a substituted citrate
JP5922609B2 (ja) 2−アミノ−3−(4−ブロモベンゾイル)フェニル酢酸含有水性組成物
US12115164B2 (en) Pemetrexed formulations
WO2019123406A1 (en) Novel formulations of vasopressin
JP2019142972A5 (https=)
KR102427941B1 (ko) 이부프로펜 및 아르기닌을 함유하는 안정성이 개선된 주사용 제제
JP7090845B2 (ja) パロノセトロン含有液体組成物
CN111346048A (zh) 一种血管内皮抑制素皮下注射剂
JPH06145043A (ja) 術中輸液製剤
BR112015001735B1 (pt) Formulação líquida de conjugado de peptídeo insulinotrópico de ação de longa duração